Atorvastatin alleviates renal ischemia-reperfusion injury in rats by promoting M1-M2 transition

Wang,Qi; Su,Yan‑Yan; Li,Yan‑Qun; Zhang,Yun‑Fang; Yang,Shen; Wang,Jie‑Lin; Li,Hong‑Yan

doi:10.3892/mmr.2016.6074

Atorvastatin alleviates renal ischemia-reperfusion injury in rats by promoting M1-M2 transition

Authors:
- Qi Wang
- Yan‑Yan Su
- Yan‑Qun Li
- Yun‑Fang Zhang
- Shen Yang
- Jie‑Lin Wang
- Hong‑Yan Li
View Affiliations

Affiliations: Department of Nephrology, Huadu District People's Hospital, Southern Medical University, Guangzhou, Guangdong 510800, P.R. China
Published online on: December 23, 2016 https://doi.org/10.3892/mmr.2016.6074
Pages: 798-804

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute kidney injury (AKI) often occurs as a result of ischemia-reperfusion (IR). Previous studies have demonstrated that inflammation is an important contributor to AKI. Atorvastatin (ATO) possesses anti‑inflammatory properties and has been demonstrated to exert protective effects against renal IR injury (IRI). However, the underlying mechanism requires further study. In the present study, a rat model of renal IRI was successfully established. Consistent with the results of a previous study, ATO significantly attenuated IRI, which was supported by a decrease in serum creatinine and an increase in creatinine clearance rate, as well as alleviated pathological alterations in renal tubular cells. There are two types of activated macrophages: Proinflammatory M1 and anti‑inflammatory M2 macrophages, which have been demonstrated to exert contributory and protective effects on IRI, respectively. The present study demonstrated that treatment with ATO significantly decreased M1 macrophage density and increased M2 macrophage density, as compared with the IR group. In addition, it is well known that M1 macrophages can be induced by T helper 1 cytokines, including tumor necrosis factor (TNF)‑α and interferon (IFN)‑γ, whereas M2 macrophages can be induced by peroxisome proliferator-activated receptor (PPAR)‑γ. The present study indicated that ATO treatment significantly decreased the expression levels of TNF‑α and IFN‑γ, and increased PPAR‑γ expression. In conclusion, ATO may ameliorate renal IRI by promoting M1‑M2 transition. Furthermore, ATO‑mediated macrophage polarization in rats with renal IRI may be associated with the downregulation of TNF‑α and IFN‑γ, and the upregulation of PPAR-γ.

View Figures

View References

1	Devarajan P: Emerging biomarkers of acute kidney injury. Contrib Nephrol. 156:203–212. 2007. View Article : Google Scholar : PubMed/NCBI
2	Kinsey GR, Li L and Okusa MD: Inflammation in acute kidney injury. Nephron Exp Nephrol. 109:e102–e107. 2008. View Article : Google Scholar : PubMed/NCBI
3	Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S and Star RA: Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 60:2118–2128. 2001. View Article : Google Scholar : PubMed/NCBI
4	Kunzendorf U, Haase M, Rolver L and Haase-Fielitz A: Novel aspects of pharmacological therapies for acute renal failure. Drugs. 70:1099–1114. 2010. View Article : Google Scholar : PubMed/NCBI
5	Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M and Ley K: Development of monocytes, macrophages, and dendritic cells. Science. 327:656–661. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ginhoux F and Jung S: Monocytes and macrophages: Developmental pathways and tissue homeostasis. Nat Rev Immunol. 14:392–404. 2014. View Article : Google Scholar : PubMed/NCBI
7	Palmer MB, Vichot AA, Cantley LG and Moeckel GW: Quantification and localization of M2 macrophages in human kidneys with acute tubular injury. Int J Nephrol Renovasc Dis. 7:415–419. 2014.PubMed/NCBI
8	Wang Y and Harris DC: Macrophages in renal disease. J Am Soc Nephrol. 22:21–27. 2011. View Article : Google Scholar : PubMed/NCBI
9	Hunter MM, Wang A, Parhar KS, Johnston MJ, Van Rooijen N, Beck PL and McKay DM: In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology. 138:1395–1405. 2010. View Article : Google Scholar : PubMed/NCBI
10	Naruszewicz M: Macrophages in the pathogenesis of atherosclerosis. Advances in science and personal observations. Kardiol Pol. 32:27–34. 1989.(In Polish). PubMed/NCBI
11	Olefsky JM and Glass CK: Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 72:219–246. 2010. View Article : Google Scholar : PubMed/NCBI
12	Murray PJ and Wynn TA: Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 11:723–737. 2011. View Article : Google Scholar : PubMed/NCBI
13	Sica A and Mantovani A: Macrophage plasticity and polarization: In vivo veritas. J Clin Invest. 122:787–795. 2012. View Article : Google Scholar : PubMed/NCBI
14	Mroz RM, Lisowski P, Tycinska A, Bierla J, Trzeciak PZ, Minarowski L, Milewski R, Lisowska A, Boros P, Sobkowicz B, et al: Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study. J Physiol Pharmacol. 66:111–128. 2015.PubMed/NCBI
15	Wu K, Lei W, Tian J and Li H: Atorvastatin treatment attenuates renal injury in an experimental model of ischemia-reperfusion in rats. BMC Nephrol. 15:142014. View Article : Google Scholar : PubMed/NCBI
16	Zhang O and Zhang J: Atorvastatin promotes human monocyte differentiation toward alternative M2 macrophages through p38 mitogen-activated protein kinase-dependent peroxisome proliferator-activated receptor γ activation. Int Immunopharmacol. 26:58–64. 2015. View Article : Google Scholar : PubMed/NCBI
17	Paller MS, Hoidal JR and Ferris TF: Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest. 74:1156–1164. 1984. View Article : Google Scholar : PubMed/NCBI
18	Xue W, Lei J, Li X and Zhang R: Trigonella foenum graecum seed extract protects kidney function and morphology in diabetic rats via its antioxidant activity. Nutr Res. 31:555–562. 2011. View Article : Google Scholar : PubMed/NCBI
19	Ghobadi H, Lari SM, Pourfarzi F, Mahmoudpour A and Ghanei M: The effects of atorvastatin on mustard-gas-exposed patients with chronic obstructive pulmonary disease: A randomized controlled trial. J Res Med Sci. 19:99–105. 2014.PubMed/NCBI
20	Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA and Griffin MD: Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int. 71:619–628. 2007. View Article : Google Scholar : PubMed/NCBI
21	Meldrum KK, Meldrum DR, Meng X, Ao L and Harken AH: TNF-alpha-dependent bilateral renal injury is induced by unilateral renal ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 282:H540–H546. 2002. View Article : Google Scholar : PubMed/NCBI
22	Donnahoo KK, Meng X, Ayala A, Cain MP, Harken AH and Meldrum DR: Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol. 277:R922–R929. 1999.PubMed/NCBI
23	Kluth DC, Erwig LP and Rees AJ: Multiple facets of macrophages in renal injury. Kidney Int. 66:542–557. 2004. View Article : Google Scholar : PubMed/NCBI
24	Ferenbach DA, Ramdas V, Spencer N, Marson L, Anegon I, Hughes J and Kluth DC: Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury. Mol Ther. 18:1706–1713. 2010. View Article : Google Scholar : PubMed/NCBI
25	Westenfelder C: Programmed anti-inflammatory macrophages protect against AKI and promote repair through trophic actions. Kidney Int. 81:939–941. 2012. View Article : Google Scholar : PubMed/NCBI
26	Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, Ruhrberg C and Cantley LG: Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 22:317–326. 2011. View Article : Google Scholar : PubMed/NCBI
27	Tontonoz P and Spiegelman BM: Fat and beyond: The diverse biology of PPARgamma. Annu Rev Biochem. 77:289–312. 2008. View Article : Google Scholar : PubMed/NCBI
28	Penas F, Mirkin GA, Vera M, Cevey Á, González CD, Gómez MI, Sales ME and Goren NB: Treatment in vitro with PPARα and PPARα ligands drives M1-to-M2 polarization of macrophages from T. cruzi-infected mice. Biochim Biophys Acta. 1852:893–904. 2015. View Article : Google Scholar : PubMed/NCBI
29	Pisanu A, Lecca D, Mulas G, Wardas J, Simbula G, Spiga S and Carta AR: Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-α agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease. Neurobiol Dis. 71:280–291. 2014. View Article : Google Scholar : PubMed/NCBI
30	Grip O, Janciauskiene S and Lindgren S: Atorvastatin activates PPAR-gamma and the inflammatory response in human monocytes. Inflamm Res. 51:58–62. 2002. View Article : Google Scholar : PubMed/NCBI